Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Apr 6;217(4):e20192312.
doi: 10.1084/jem.20192312.

The omentum, a niche for premetastatic ovarian cancer

Affiliations
Comment

The omentum, a niche for premetastatic ovarian cancer

Xiaojing Ma. J Exp Med. .

Abstract

The work by Etzerodt et al. in this issue of JEM (https://doi.org/10.1084/jem.20191869) identifies a distinct omentum-resident macrophage population of embryonic origin and demonstrates that these cells provide a niche for ovarian cancer metastasis and cancer stemness. This research opens up for many questions and therapeutic prospects.

PubMed Disclaimer

Figures

None
Insights from Xiaojing Ma.
None
Ovarian cancer most frequently develops from the fallopian tube epithelium or ovarian surface epithelium. Tumor cells disseminate to the peritoneal cavity at early stages and most frequently colonize the omentum. Etzerodt et al. (2020) identify a subset of TRMs in omentum of embryonic origins that coexpress CD163 and Tim4. The study shows that these TRMs promote the malignant progression of OCCs and the acquisition of invasive properties in a paracrine manner leading to the metastatic spread of disease. The study further reveals that CD163+Tim4+ TRMs in omentum represent a critical premetastatic niche for OCCs and a potentially important therapeutic target to prevent disease progression. FALC, fat-associated lymphoid cluster. Adapted from Dr. T. Lawrence of King's College London.

Comment on

Similar articles

Cited by

References

    1. Coffman L.G., et al. Transl. Res. 2016 doi: 10.1016/j.trsl.2016.03.016. - DOI - PMC - PubMed
    1. Etzerodt A., et al. J. Exp. Med. 2020 doi: 10.1084/jem.20191869. - DOI - PubMed
    1. Gerber S.A., et al. Am. J. Pathol. 2006 doi: 10.2353/ajpath.2006.051222. - DOI - PubMed
    1. Ginestier C., et al. J. Clin. Invest. 2010 doi: 10.1172/JCI39397. - DOI - PubMed
    1. Lan C., et al. Technol. Cancer Res. Treat. 2013 doi: 10.7785/tcrt.2012.500312. - DOI - PubMed